


## Motixafortide

## Chemical Properties

CAS No. :	664334-36-5
Formula:	C97H144FN33O19S2
Molecular Weight:	2159.52
Storage:	Keep away from moisture Powder: -20°C for 3 years   In solvent: -80°C for 1 year <small>Actual storage temperature shall be subject to the COA.</small>



## Biological Description

Description	Motixafortide (BKT140 4-fluorobenzoyl) is a CXCR4 antagonist with an IC50 of 1 nM.
Targets(IC50)	CXCR
In vitro	Motixafortide (BKT140) exhibits selective toxicity against AmL and MM cells by specifically inducing CXCR4-dependent and apoptotic cell death in these leukemia and multiple myeloma (MM) cell types. Additionally, treatment with Motixafortide (BKT140) counteracts the IL-6 dependent proliferation and survival observed in ARH77 MM cells.
In vivo	Treatment with Motixafortide (BKT140) results in reduced size and weight of tumors in animals, alongside increased necrotic areas and elevated apoptotic scores[2]. Additionally, subcutaneous administration of Motixafortide (BKT140) markedly diminishes the growth of human acute myeloid leukemia and multiple myeloma xenografts in a dose-dependent fashion.

## Solubility Information

Solubility	DMSO: 36 mg/mL (16.67 mM), Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
------------	--

### Preparing Stock Solutions

---

	1mg	5mg	10mg
1 mM	0.4631 mL	2.3153 mL	4.6307 mL
5 mM	0.0926 mL	0.4631 mL	0.9261 mL
10 mM	0.0463 mL	0.2315 mL	0.4631 mL
50 mM	0.0093 mL	0.0463 mL	0.0926 mL

---

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

### Reference

Peled A, et al. The high-affinity CXCR4 antagonist BKT140 is safe and induces a robust mobilization of human CD34+ cells in patients with multiple myeloma. Clin Cancer Res. 2014 Jan 15;20(2):469-79.

Beider K, et al. CXCR4 antagonist 4F-benzoyl-TN14003 inhibits leukemia and multiple myeloma tumor growth. Exp Hematol. 2011 Mar;39(3):282-92.

**Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins**

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel: 781-999-4286 E\_mail: info@targetmol.com Address: 34 Washington Street, Wellesley Hills, MA 02481